These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35538045)

  • 1. Dynamic changes in systemic immune-inflammation index predict pathological tumor response and overall survival in patients with gastric or gastroesophageal junction cancer receiving neoadjuvant chemotherapy.
    Demircan NC; Atcı MM; Demir M; Işık S; Akagündüz B
    Asia Pac J Clin Oncol; 2023 Feb; 19(1):104-112. PubMed ID: 35538045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor regression grade combined with post-therapy lymph node status: A novel independent prognostic factor for patients treated with neoadjuvant therapy followed by surgery in locally advanced gastroesophageal junction and gastric carcinoma.
    Yin H; Yao Q; Xie Y; Niu D; Jiang W; Cao H; Feng X; Li Y; Li Y; Zhang X; Shen L; Chen Y
    Cancer Med; 2023 Oct; 12(19):19633-19643. PubMed ID: 37749981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
    Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J
    J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
    Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
    J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Interleukin 6 Level is Associated With Overall Survival and Treatment Response in Gastric and Gastroesophageal Junction Cancer.
    Karalis JD; Ju MR; Yoon LY; Castro-Dubon EC; Reznik SI; Hammer STG; Porembka MR; Wang SC
    Ann Surg; 2023 Dec; 278(6):918-924. PubMed ID: 37450705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis.
    Li Z; Shan F; Wang Y; Zhang Y; Zhang L; Li S; Jia Y; Xue K; Miao R; Li Z; Ji J
    PLoS One; 2018; 13(1):e0189294. PubMed ID: 29370182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
    Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
    BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of tumor regression grade following the administration of neoadjuvant chemotherapy as treatment for gastric/gastroesophageal adenocarcinoma: A meta-analysis of 14 published studies.
    Hayashi M; Fujita T; Matsushita H
    Eur J Surg Oncol; 2021 Aug; 47(8):1996-2003. PubMed ID: 33353828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined systemic inflammatory immune index and prognostic nutrition index as chemosensitivity and prognostic markers for locally advanced gastric cancer receiving neoadjuvant chemotherapy: a retrospective study.
    Ding P; Yang J; Wu J; Wu H; Sun C; Chen S; Yang P; Tian Y; Guo H; Liu Y; Meng L; Zhao Q
    BMC Cancer; 2024 Aug; 24(1):1014. PubMed ID: 39148031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
    Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 12. Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB.
    Liu P; Jiang Y; Zheng X; Pan B; Xiang H; Zheng M
    Pathol Oncol Res; 2022; 28():1610294. PubMed ID: 35570842
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluating Treatment Response in GEJ Adenocarcinoma: The Role of Pretherapeutic and Posttherapeutic Iodine Mapping.
    Graf M; Gawlitza J; Makowski M; Meurer F; Huber T; Ziegelmayer S
    Invest Radiol; 2024 Aug; 59(8):583-588. PubMed ID: 38265075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response.
    Xu X; Zheng G; Zhang T; Zhao Y; Zheng Z
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):635-646. PubMed ID: 31230156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator.
    Chen L; Chen Y; Zhang L; Xue Y; Zhang S; Li X; Song H
    Pathol Oncol Res; 2021; 27():1609811. PubMed ID: 34712105
    [No Abstract]   [Full Text] [Related]  

  • 16. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study.
    Ding P; Guo H; Sun C; Yang P; Kim NH; Tian Y; Liu Y; Liu P; Li Y; Zhao Q
    BMC Gastroenterol; 2022 Mar; 22(1):121. PubMed ID: 35287591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study.
    Başoğlu T; Sakin A; Erol C; Özden E; Çabuk D; Çılbır E; Tataroğlu Özyükseler D; Ayhan M; Şendur MA; Dogan M; Öksüzoğlu B; Eryılmaz MK; Er Ö; Taşçı EŞ; Özyurt N; Dülgar Ö; Özen M; Hacıbekiroğlu İ; Öner İ; Bekmez ET; Çağrı Yıldırım H; Yalçın Ş; Paydaş S; Yekedüz E; Aksoy A; Özçelik M; Oyman A; Almuradova E; Karabulut B; Demir N; Dinçer M; Özdemir N; Erdem D; Ak N; İnal A; Salim DK; Deniz Gİ; Şakalar T; Gülmez A; Kaçan T; Özdemir Ö; Alan Ö; Ünal Ç; Karakaş Y; Turhal S; Yumuk PF
    J Chemother; 2023 Apr; 35(2):142-149. PubMed ID: 35579894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
    Huang T; Zhang H; Zhao Y; Li Y; Wang G; Zhang Y; Guo D; Ji S; Sun Z
    Future Oncol; 2021 Jun; 17(17):2141-2149. PubMed ID: 33635094
    [No Abstract]   [Full Text] [Related]  

  • 19. The Change of Systemic Immune-Inflammation Index Independently Predicts Survival of Colorectal Cancer Patients after Curative Resection.
    Chen Q; Wu H; Guo X; Gu K; Wang W; Chen X; Ji S; Yang H; Zhu J
    Mediators Inflamm; 2020; 2020():4105809. PubMed ID: 33293896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value and clinicopathological correlation of the tumor regression grade in neoadjuvant chemotherapy for gastric adenocarcinoma: a retrospective cohort study.
    Wang Y; Xu H; Hu C; Yu P; Bao Z; Zhang Y; Zhang R; Zhang S; Li B; Aerts JM; Xu Z; Cheng X
    J Gastrointest Oncol; 2022 Jun; 13(3):1046-1057. PubMed ID: 35837180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.